A detailed history of Jump Financial, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 9,080 shares of AXSM stock, worth $884,119. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,080
Previous 27,119 66.52%
Holding current value
$884,119
Previous $2.18 Million 62.67%
% of portfolio
0.02%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.93 - $95.84 $1.42 Million - $1.73 Million
-18,039 Reduced 66.52%
9,080 $815,000
Q2 2024

Aug 14, 2024

BUY
$65.72 - $80.5 $1.78 Million - $2.18 Million
27,119 New
27,119 $2.18 Million
Q4 2023

Oct 21, 2024

SELL
$57.42 - $83.61 $5,052 - $7,357
-88 Reduced 1.04%
8,400 $668,000
Q4 2023

Feb 07, 2024

BUY
$57.42 - $83.61 $482,328 - $702,324
8,400 New
8,400 $668,000
Q2 2023

Oct 21, 2024

SELL
$58.41 - $90.35 $3.01 Million - $4.65 Million
-51,503 Reduced 85.85%
8,488 $609,000
Q2 2023

Aug 07, 2023

SELL
$58.41 - $90.35 $3.01 Million - $4.65 Million
-51,503 Reduced 85.85%
8,488 $609,000
Q1 2023

Oct 21, 2024

BUY
$58.39 - $75.0 $1.92 Million - $2.47 Million
32,872 Added 121.21%
59,991 $3.7 Million
Q1 2023

May 03, 2023

BUY
$58.39 - $75.0 $1.59 Million - $2.04 Million
27,241 Added 83.18%
59,991 $3.7 Million
Q4 2022

Feb 13, 2023

SELL
$39.94 - $79.72 $185,161 - $369,581
-4,636 Reduced 12.4%
32,750 $2.53 Million
Q3 2022

Nov 07, 2022

BUY
$36.06 - $69.85 $1.35 Million - $2.61 Million
37,386 New
37,386 $1.67 Million
Q2 2021

Aug 13, 2021

SELL
$50.63 - $73.5 $632,875 - $918,750
-12,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$55.91 - $81.44 $698,875 - $1.02 Million
12,500 New
12,500 $708,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $4.18B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.